ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
A loss of -1.530% shows a downward development for ProQR Therapeutics N.V..
ProQR Therapeutics N.V. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 3 € there is potential for a 102.43% increase which would mean more than doubling the current price of 1.48 € for ProQR Therapeutics N.V..
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 7 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | -1.530% | 3.083% | -2.101% | -16.185% | -8.507% | 6.806% | -65.973% |
| Pharming Group | 3.260% | -3.709% | -5.643% | 27.646% | -22.778% | 0.593% | 13.529% |
| Formycon AG | -1.170% | 5.399% | -2.700% | -38.152% | -26.654% | -70.901% | -68.237% |
| Evolus Inc | -1.060% | 1.648% | -18.890% | -36.775% | -7.193% | -23.940% | -45.319% |
Comments
ProQR Therapeutics (PRQR) had its price target lowered by JonesTrading from $11.00 to $10.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat